Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 701–800 of 1,000
Síndrome de intestino irritable (SII): Nuevos conceptos en 2023.
William Otero, R., Lina Otero, P., & Hernando Marulanda, F. (2022) · Medicina · doi:10.56050/01205498.2182 · Cited by 6
Arora, U., Sachdeva, K., Garg, P., Baitha, U., Kedia, S., Kalaivani, M., Ahuja, V., Kumar, A., Ranjan, P., Vikram, N. K., et al. (2023) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001872 · Cited by 4
“For Pimentel et al 16 the postintervention mean scores were available after communication with the authors, while the postintervention SDs were substituted from the baseline SD since it was reasonable to assume that the interventions did not alter the variability of this outcome measure for the…”
BackgroundMethodInfluentialKerbage, A., Loesch, J., Hamza, E., Khan, S., Nero, N., Simons, M. L., & Lembo, A. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003099 · Cited by 4
Self-citationReizdarmsyndrom – Diagnostik und Therapie
Pohl, D., Heinrich, H. S., & Misselwitz, B. (2013) · Die Gastroenterologie · doi:10.1007/s11377-013-0783-1 · Cited by 3
Hanaway, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35868-2.00041-4 · Cited by 4
Síndrome del intestino irritable: cómo mejorar la toma de decisiones en la práctica clínica
Mearin, F., Rey, E., & Santander, C. (2018) · Medicina Clínica · doi:10.1016/j.medcli.2018.06.020 · Cited by 3
Jia, Y., Guo, L., Yang, S., Wu, Q., & Meng, F. (2019) · Frontiers of Nursing · doi:10.2478/fon-2019-0018 · Cited by 3
Koloski, N. A., & Talley, N. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-384978-6.00092-3 · Cited by 3
Scientific Evidence for the Treatment of Children with Irritable Bowel Syndrome
Quitadamo, P., Isoldi, S., Mallardo, S., Zenzeri, L., & Nardo, G. D. (2021) · Current Pediatric Reviews · doi:10.2174/1573396317666210127123330 · Cited by 4
“Adult studies support its use expecially in non constipation-type IBS [52, 53].”
BackgroundResultIrritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity
Cunningham, A. L., Palomero, O. E., Voss, B. J., Trent, M. S., & Davies, B. W. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-21 · Cited by 3
Funktionelle Diarrhoe – Pathophysiologie, Abklärung und Therapie
Schaub, N., & Degen, L. P. (2014) · Therapeutische Umschau · doi:10.1024/0040-5930/a000551 · Cited by 4
Schmerztherapie beim Reizdarmsyndrom
de Greck, M., Layer, P., & Andresen, V. (2014) · Der Schmerz · doi:10.1007/s00482-014-1406-6 · Cited by 3
Therapeutische Modulation der Darmmikrobiota beim Reizdarmsyndrom
Konturek, P. C., & Zopf, Y. (2017) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-017-0338-3 · Cited by 5
The Influence of Microbiota on Gastrointestinal Motility
Raja, S. M., Batra, V., & Srinivasan, S. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7534-1_6 · Cited by 3
Айтбаев, К. А., Murkamilov, I., Fomin, V. V., Yusupov, F. A., Redjapova, N., Raimzhanov, Z., & Aidarov, Z. (2018) · Medical news of the North Caucasus · doi:10.14300/mnnc.2018.13033 · Cited by 3
“Назначение рифаксимина в дозе 550 мг 3 раза в день по сравнению с плацебо способствовало адекватному облегчению общих симптомов СРК (40,7 % против 31,7 % соответственно, p<0,01) или вздутия живота (40,2 % против 30,3 % соответственно, p<0,001) [34].”
Mearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2017) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2017.01.001 · Cited by 6
NON-ANTIBIOTIC USE OF ANTIBIOTICS
Danielewski, M., Ksiądzyna, D., & Szeląg, A. (2018) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.21307/pm-2018.57.4.301 · Cited by 3
“12 weeks after antibiotic treatment [69].”
Vanderberg, R., Lu, A. D., & Hashash, J. G. (2020) · Springer eBooks · doi:10.1007/978-3-030-50695-7_27 · Cited by 3
Rifaximin for Irritable Bowel Syndrome without Constipation
Krause, R., Zollner‐Schwetz, I., & Valentin, T. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1101839 · Cited by 4
How effective are antibiotics for the treatment of irritable bowel syndrome?
Black, C. J., & Ford, A. C. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1808623 · Cited by 2
Antibiotic treatment for small intestinal bacterial overgrowth: Is a cocktail better than a single?
Ghoshal, U. C. (2021) · United European Gastroenterology Journal · doi:10.1002/ueg2.12075 · Cited by 3
Ford, A. C. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch20 · Cited by 5
Gut Microbiome and Its Role in the Pathophysiology of Irritable Bowel Syndrome
Palma, G. D., & Berčík, P. (2021) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/dxfc9250 · Cited by 4
Andrews, M. B., & Adler, D. G. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2490841 · Cited by 2
“These studies included two phase 3 randomized controlled trials (sponsored by the drug maker Salix Pharmaceuticals, Raleigh, NC) which assessed 14-day treatment with rifaximin and reported no AEs of C. difficile or deaths [12].”
Yamane, T., Masaoka, T., Ishii, C., Masuoka, H., Suda, W., Kurokawa, S., Kishimoto, T., Mikami, Y., Fukuda, S., & Kanai∥, T. (2025) · Digestion · doi:10.1159/000545183 · Cited by 3
“IBS treat-ment strategies that target the gut microbiota include low fermentable oligosaccharides, disaccharides, monosac-charides, and polyols diet therapy [14 – 16]; prebiotics [17, 18]; probiotics [19, 20]; and antibiotics [21, 22].”
Remes-Troche, J. M., Coss‐Adame, E., Schmulson, M. J., García‐Zermeño, K. R., Amieva‐Balmori, M., Carmona-Sánchez, R., Gomez-Escudero, O., Gómez-Castaños, P. C., Icaza-Chávez, M. E., López‐Colombo, A., et al. (2025) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2024.10.009 · Cited by 13
Hong, G., Zhao, Y., & Hou, X. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178271 · Cited by 3
Alam, M., Abbas, K., Khan, M., Saini, R. S., & Faraz, M. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02317-8 · Cited by 2
Wadlund, D. L. (2012) · The Nurse Practitioner · doi:10.1097/01.npr.0000413481.44379.24 · Cited by 2
Diagnosis and Treatment of Functional Bloating
Park, M. I. (2012) · Korean Journal of Medicine · doi:10.3904/kjm.2012.83.5.562 · Cited by 2
“비흡수성 항생제인 rifaximin이 팽만감에 대한 치료제로서 시도되어왔다[42-44].”
Quigley, E. M. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00039-3 · Cited by 4
Oral serum bovine immunoglobulin improves IBS-D symptoms analyzed from patient medical charts.
Good, L. I., Shaw, A. L., Wei, D., Vasquez, R. E., Panas, R. M., Jackson, B., Bradshaw, T., Burnett, B. P., & The SBI Retrospective Study Group (2017) · doi:10.35841/biology-medicine.1.1.16-23 · Cited by 1
Self-citationOh, S. J., Tashjian, V. C., Mirocha, J., Nagar, M., Mathur, R., Lin, E. A., Chua, K. S., Rezaie, A. R., Pimentel, M., & Pichetshote, N. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5302-2 · Cited by 3
Self-citationReizdarmsyndrom und funktionelle Dyspepsie: Diagnostik und Therapie
Gottschalk, L., Andresen, V., & Layer, P. (2022) · Der Internist · doi:10.1007/s00108-021-01218-3 · Cited by 3
Hershko‐Moshe, A., Hasin, Y., Nevo-Shor, A., Etzion, O., & Ilan, Y. (2022) · GastroHep · doi:10.1155/2022/1192547 · Cited by 2
“Rifaximin is a broad-spectrum nonabsorbable antibiotic that appears beneficial after two weeks of treatment, alleviating abdominal pain and bloating and relieving diarrhea [32].”
BackgroundInteraction of Intestinal Microbiota with Medications
Liu, M., Xu, J., Jin, Q., & Li, Y. (2023) · Current Drug Metabolism · doi:10.2174/1389200224666230418104540 · Cited by 2
Adams, M. D., Muftaudeen, T. K., & Saliu, O. A. (2023) · Nigerian Journal of Biochemistry and Molecular Biology · doi:10.4314/njbmb.v38i3.4 · Cited by 2
Marasco, G., Cremon, C., Barbaro, M. R., Stanghellini, V., & Barbara, G. (2024) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001964 · Cited by 5
Serra, J., Aguilar, A., Barba, E., Ríos, C. C. D. L., Pravia, L. G., Martínez, V., & Falcón, B. S. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2024.02.005 · Cited by 2
Karki, B., Sherpa, T. W., Deo, R. K., & Thapa, P. (2024) · Journal of Patan Academy of Health Sciences · doi:10.3126/jpahs.v11i1.65652 · Cited by 2
“7,8 Yet, research on treatment response among Nepalese IBS patients is scant.”
BackgroundSmall intestinal bacterial overgrowth: from malabsorption to misinterpretation
Quigley, E. M. M. (2025) · Minerva Gastroenterology · doi:10.23736/s2724-5985.24.03781-1 · Cited by 6
Schmulson (2025) · doi:10.1016/j.rgmx.2024.10.003 · Cited by 3
“…inmune de la mucosa, mejoría de la permeabilidad intestinal, e incremento en la comuni-cación intestino-cerebro La mayoría de estos efectos se han demostrado en estudios in vitro o en animales de expe-rimentación y son muy escasos los estudios mecanísticos de probióticos en humanos Se ha…”
Modulation of the Gut Ecosystem in Irritable Bowel Syndrome
König, J., & Brummer, R. J. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_4 · Cited by 2
Irritable Bowel Syndrome: Pathophysiology and Goals of Therapy
Schoenfeld, P., Lembo, A. J., Cash, B. D., & Pimentel, M. (2015) · Cited by 2
Self-citationProbiotics for irritable bowel syndrome: Should we give them full names?
Álvarez-Sánchez, Á., & Rey, E. (2013) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082013000100001 · Cited by 2
When to Reconsider the Diagnosis of Irritable Bowel Syndrome
Hammerle, C. W., & Crowe, S. E. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.03.011 · Cited by 3
Perhaps it is time to rethink IBS-D
Habba, S. F. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.610007 · Cited by 2
Existing and emerging therapies for irritable bowel syndrome
Acosta, R. D., & Cash, B. D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.566214 · Cited by 2
Uno, Y. (2015) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2015.511025 · Cited by 2
“Nevertheless, effectiveness of the eradication of IBS was reported, as bacterial growth was implicated in development of the syndrome [16].”
BackgroundClinical Pearls for Irritable Bowel Syndrome: Management of the Diarrhea-Predominant Subtype
Lacy, B. E., & OʼShana, T. (2014) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000056 · Cited by 2
Tominaga, K., Fujikawa, Y., Tanaka, F., Tanigawa, T., Watanabe, T., Fujiwara, Y., & Arakawa, T. (2015) · Journal of General and Family Medicine · doi:10.14442/jgfm.16.4_242 · Cited by 2
The Microbiome in Neurogastroenterology
Preidis, G. A., Chumpitazi, B. P., & Shulman, R. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-43268-7_5 · Cited by 2
Yue, L., Chen, M., Tang, T., She, T., Chen, Y.-Y., & Zheng, H. (2018) · Medicine · doi:10.1097/md.0000000000011682 · Cited by 2
Jung, H. (2018) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2018.72.5.252 · Cited by 2
“최근에 발표된 몇몇의 무작위 대조시험에 서 리팍시민은 설사 우세형 과민성장증후군에서 복통, 복부 팽만감, 대변 성상의 정상화에 효과가 있으며 증상이 재발하 는 경우에도 반복적인 치료가 효과적이다.(23-27) 소화관에서 흡 수가 잘 되지 않아 부작용이 거의 없다.”
Small intestinal bacterial and fungal overgrowth
Bhagatwala, J., & Rao, S. S. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813037-7.00024-8 · Cited by 2
Irritable bowel syndrome with diarrhea: Treatment is a work in progress
Kurin, M., & Cooper, G. S. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.19011 · Cited by 5
Engin, Ö., Uyar, M. E., Sunamak, O., & İpekçi, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-17993-3_5 · Cited by 2
Emerging therapies in the management of Irritable Bowel Syndrome (IBS)
Elwing, J. E., Atassi, H., Rogers, B. D., & Sayuk, G. S. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2052043 · Cited by 2
Kim, N. (2022) · Springer eBooks · doi:10.1007/978-981-19-0120-1_16 · Cited by 3
Atay, O. K., David, J. G., & Mehta, A. (2022) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2022.06.005 · Cited by 2
Probiotics and Irritable Bowel Syndrome
Qureshi, I., & Endres, J. R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-397154-8.00027-0 · Cited by 2
Schoenfeld, P., & Pimentel, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12837 · Cited by 2
“for 14 days is the recommended dose.(3) The third RCT discussed in our study is a phase 2 dose-ranging study to identify the ideal dose for treatment of non-C IBS.”
BackgroundSelf-citationEditorial: safety and tolerability of rifaximin for IBS – more information is required
Cai, S., & Yang, Y. S. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12769 · Cited by 2
“7% improvement in placebo group.(2) Treatment for IBS with rifaximin should be prudent.”
BackgroundSachdeva, S., Kondala, R., Dahale, A. S., & Puri, A. S. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3352-7 · Cited by 2
Bacterial, Viral, and Toxic Causes of Diarrhea, Gastroenteritis, and Anorectal Infections
Cohen, M. B. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch62 · Cited by 2
Activation of T-regulatory cells by a synbiotic may be important for its anti-inflammatory effect
Chen, J., & Vitetta, L. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-02080-8 · Cited by 2
Videlock, E. J., & Chang, L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch75 · Cited by 2
Bielefeldt, K., & Gebhart, G. F. (2022) · Wiley eBooks · doi:10.1002/9781119701170.ch34 · Cited by 4
Is rifaximin an effective treatment option for irritable bowel syndrome?
SMITH, R. E., & Crone, W. (2011) · JAAPA · doi:10.1097/01720610-201112000-00017 · Cited by 1
Abdominal pain models: mechanisms and therapies and experimental models
Lucarini, E., Mannelli, L. D. C., & Ghelardini, C. (2020) · doi:10.36118/pharmadvances.03.2020.04 · Cited by 1
Use of Rifaximin in Irritable Bowel Syndrome Treatment
Wróblewski, H., & Zimna, A. I. (2021) · Journal of Education Health and Sport · doi:10.12775/jehs.2021.11.08.025 · Cited by 2
“Ponadto, znacznie więcej otrzymujących ryfaksyminę wykazało odpowiedź na leczenie, ocenianą na podstawie dziennych ocen objawów IBS, wzdęć, bólu brzucha i konsystencji stolca.(9) W 2015 r.”
Antonio Romano, Balestrini, L., Scala, G. D., Chico, L., Alessio Bertini, Cangioli, M., Ciapparelli, F., Ciardella, E., Congestrì, C., Dinelli, V., et al. (2024) · Journal of Dietary Supplements · doi:10.1080/19390211.2023.2296106 · Cited by 1
“Several evidence from literature in adults support the beneficial effect of this poorly absorbable antibiotic on IBS without constipation, being the treatment effective and safe (Pimentel et al. 2011; Ford et al. 2018; Rezaie et al. 2019).”
BackgroundRifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial
Becker, S., Grode, L. B., & Bonderup, O. K. (2024) · Inflammatory Intestinal Diseases · doi:10.1159/000536124 · Cited by 1
“It is approved for the treatment of traveller ’ s diarrhoea, small intestinal bacterial overgrowth [16], and irritable bowel syndrome [17, 18].”
BackgroundLacy, B. E., Gagnon‐Sanschagrin, P., Heimanson, Z., Bungay, R., Bellefleur, R., Guérin, A., Bumpass, B., Borroto, D., Joseph, G., & Dashputre, A. A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02832-x · Cited by 1
“…medications in patients with IBS-D [4, 7] and both have shown significant improvement in clinical outcomes assessed in their respective clinical trials [11–13], no head-to-head studies or comprehensive comparisons of their clinical and economic outcomes in a real-world setting have been conducted.”
Colorectal Diseases and Gut Microbiome
Kim, N. (2024) · Springer eBooks · doi:10.1007/978-981-97-0130-8_6 · Cited by 4
Fujikawa, Y., & Tominaga, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-8410-3_11 · Cited by 1
Chaudhry, N., Eriksson, S. E. S., Sarici, I. S., Swanson, K. J., Hanuschock, S., DeWitt, A. M., Zheng, P., & Ayazi, S. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12092-7 · Cited by 1
“Another large clinical trial reported bloating relief in 40.2% of patients treated with rifaximin versus 30.3% in the placebo group [21].”
InfluentialSmall bowel obstruction by a giant fecal bezoar in a blind loop of small intestine: a case report
Chen, Z., Wu, Y., & Xi, K. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1644026 · Cited by 1
“Treatment involves surgical resection of the blind loop (if feasible) and fecal bezoar removal, alongside antibiotics (e.g., rifaximin) for bacterial overgrowth (10).”
Vermeijden, N. K., Oorthuys, A. O. J., Groen, J., Thapar, N., Vlieger, A. M., Puoti, M. G., Borrelli, O., & Benninga, M. A. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2582017 · Cited by 1
“Rifaximin is an oral, non-systemic, broad-spectrum antibiotic that primarily targets the gut microbiota and is associated with a low risk of bacterial resistance [119].”
Tabesh, E., Alipour, Z., Soheilipour, M., & Hosseinian, S.-Z. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02123-8 · Cited by 1
“This response rate is consistent with other trials in IBS populations without constipation, where antibiotics such as rifaximin, administered without prior breath testing, typically improve bloating in approximately 40% of patients [34].”
Wei, Q., Rui, M., Wang, Y., Ng, S. C., & You, J. H. S. (2025) · Digestion · doi:10.1159/000549485 · Cited by 1
Abdominal Pain After Bariatric Surgery and the Role of the Gut: A Review
de Louweren, B., Nieuwdorp, M., & Gerdes, V. E. A. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01844-w · Cited by 1
“Pimentel et al. studied the use of rifaximin in patients with IBS; 40.8% of these patients reported adequate decrease in bloating and abdominal pain compared to 31.2% in the placebo group [57].”
InfluentialORP-101 in Irritable Bowel Syndrome With Diarrhea: A Phase II Randomized, Controlled Trial
Singh, P., Nee, J. W., Ballou, S., Lee, A., Loesch, J., Iturrino, J., Rangan, V., & Lembo, A. J. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.03.012 · Cited by 1
Self-citationPastras, P., Aggeletopoulou, I., Psalti, V., & Triantos, C. K. (2026) · Pharmaceuticals · doi:10.3390/ph19050783 · Cited by 2
“…resulted in a significantly higher proportion of patients reporting adequate relief of overall IBS symptoms during the first 4 weeks after treatment compared with placebo (40.7% vs. 31.7% p 0.001 in the two studies combined), as well as relief of bloating (40.4% vs. 30.3%, p 0.001) [85].”
InfluentialChoudhary, A. K., Hait, A., Ganesan, S., Howlader, S., & Periasamy, P. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00646-7 · Cited by 3
“A pooled sensitivity of approximately 55% and specificity above 80% indicate that a positive GBT result meaningfully increases the probability of SIBO, whereas a negative result does not reliably exclude disease [34, 35].”
Zhong, J., Xu, Z., Chen, W., Jiang, Y., Ge, Q., Deng, Y., He, W., Mao, X., 朱雅碧, Sang, J., et al. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70672 · Cited by 1
“Rifaximin is a non-systemic, broad-spectrum oral antibiotic confined to the gastrointestinal tract that stabilizes gut microbiota [15, 16].”
Bach, C., Schiebel, C. S., Braga, L. L. V. D. M., Fernandes, A. C. V. U., Avancini, M., Fernandes, G. F., Zaleski, J., D'Agostin, J. B., & Ferreira, D. M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1810632 · Cited by 1
“Randomized controlled trials and meta-analyses have demonstrated modest but clinically meaningful efficacy for these therapies (Pimentel et al., 2011; Menees et al., 2012; Riddle et al., 2016).”
Lasa, J. S., & Zubiaurre, I. (2016) · International Journal of Celiac Disease · doi:10.12691/ijcd-2-2-9 · Cited by 1
[Variation of intestinal fermentative profile after sequential therapy with rifaximin/probiotics].
Dima, G., Peralta, D., Novillo, A., Lasa, J. S., Besasso, H. R., & Soifer, L. (2012) · PubMed · Cited by 3
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Lorenzetti, R., & Prantera, C. (2013) · Clinical Investigation · doi:10.4155/cli.13.96 · Cited by 1
Automatic Evaluation of Gastrointestinal Motor Activity through the Analysis of Bowel Sounds
Shono, K., Emoto, T., Okahisa, T., Abeyratne, U. R., Yano, H., Akutagawa, M., Konaka, S., & Kinouchi, Y. (2013) · Biomedical Engineering · doi:10.2316/p.2013.791-069 · Cited by 1
Reizdarmsyndrom wird immer besser verstanden
Lambertz, J., Allescher, H., & Garmisch-Partenkirchen (2014) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-014-3643-0 · Cited by 1
Rifaximin provides effective and sustained relief of IBS symptoms
Nanda, S. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.10 · Cited by 1
Lobo, B. (2013) · TDX (Tesis Doctorals en Xarxa) · Cited by 1
Probiotics: defenders of gastrointestinal habitats
Singh, D. D., Amdeka, S., & Singh, V. K. (2012) · Gastroenterology Insights · doi:10.4081/gi.2012.e22 · Cited by 1
Symbiotics, Probiotics, and Fiber Diet in Diverticular Disease
Lahner, E., & Annibale, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00035-6 · Cited by 1
Progress with treating the microbial dysbiosis associated with irritable bowel syndrome
Pearson, J. S., & Whorwell, P. J. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000328 · Cited by 2
“antibiotic, which has demonstrated sustained efficacy in patients with nonconstipation type IBS in the Targeted non-systemic antibiotic rifaximin gut-selective evaluation of treatment for non-C IBS (TARGET) trial series [6].”
BackgroundNoureddine, M., Issa, I. A., & Moucari, R. (2015) · Cited by 1
Assouline-Dayan, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-59352-4_38 · Cited by 1
Thurm, T., & Ron, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-59352-4_32 · Cited by 1
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.